Clinical trial research in focus: overcoming barriers in MDR-TB clinical trials

The Lancet Respiratory Medicine

Volumn 5, Issue 4, 2017, Pages 247-248

  Zumla, Alimuddin ^a   Abubakar, Ibrahim ^b  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NEW DRUG; TUBERCULOSTATIC AGENT;

CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); DISABILITY; HUMAN; INCIDENCE; LUNG INJURY; MULTIDRUG RESISTANT TUBERCULOSIS; NOTE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETURN TO WORK; TREATMENT OUTCOME; ADULT; CHILD; ECONOMICS; FEMALE; GLOBAL HEALTH; MALE; MEDICAL RESEARCH; METHODOLOGY; STANDARDS;

ADULT; ANTITUBERCULAR AGENTS; BIOMEDICAL RESEARCH; CHILD; FEMALE; GLOBAL HEALTH; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 85016130865     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(17)30091-7     Document Type: Note

References (11)

1. 1 WHO. WHO global tuberculosis report 2016. WHO/HTM/2016.13.1-214. http://www.who.int/tb/publications/global_report/en/ (accessed Feb 28, 2017).
2. 2 WHO. WHO treatment guidelines for drug-resistant tuberculosis, 2016 update, 2016, World Health Organization, Geneva.
3. 3 Wallis, RS, Maeurer, M, Mwaba, P, et al. Tuberculosis—advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers. Lancet Infect Dis 16 (2016), e34–e46.
4. 4 Zumla, A, Rao, M, Wallis, RS, et al., Host-Directed Therapies Network consortium. Host-directed therapies for infectious diseases: current status, recent progress, and future prospects. Lancet Infect Dis 16 (2016), e47–e63.
5. 5 Mitnick, C, Rusen, ID, Bain, LJ, Horsburgh, J, Issues in design and interpretation of MDR-TB clinical trials: report of the first Global MDR-TB clinical trials landscape meeting. BMC Proc, 9(suppl 8), 2015, 51.
6. 6 Phillips, PPJ, Methodological considerations in clinical trials for new MDR-TB treatment regimens. Int J Tuber Lung Dis 20 (2016), 54–57.
7. 7 McAnaw, SE, Hesseling, AC, Seddon, JA, et al. Pediatric multidrug-resistant tuberculosis clinical trials: challenges and opportunities. Int J Infect Dis, 2016, 10.1016/j.ijid.2016.11.423 published online Dec 9.
8. 8 Furin, J, Alirol, E, Allen, E, et al. Drug resistant tuberculosis clinical trials: proposed core research definitions in adults. Int J Tuberc Lung Dis 20 (2016), 290–294.
9. 9 Cellamare, M, Milstein, M, Ventz, S, Baudin, E, Trippa, L, Mitnick, CD, Bayesian adaptive randomization in a clinical trial to identify new regimens for MDR-TB: the endTB trial. Int J Tuberc Lung Dis 20 (2016), 8–12.
10. 10 Petruccioli, E, Scriba, TJ, Petrone, L, et al. Correlates of tuberculosis risk: predictive biomarkers for progression to active tuberculosis. Eur Respir J 48 (2016), 1751–1763.
11. 11 Tupasi, T, Gupta, R, Danilovits, M, et al. Building clinical trial capacity to develop a new treatment for multidrug-resistant tuberculosis. Bull World Health Org 94 (2016), 147–152.